The HSV gene encoding ICP4 is negatively regulated and the HSV gene encoding thymidine kinase is positively regulated by ICP4 in vivo. We report that ICP4 is a component of a stable complex that contains protein and a sequence of approximately 28 nucleotides that span the ICP4 gene transcription initiation site. The association of ICP4 with DNA sequences between positions -103 and +32 relative to the ICP4 mRNA start site was demonstrated by DNA binding immunoassays. DNase footprinting revealed that nucleotides between positions -8 and +20 are protected by ICP4. In contrast, binding of ICP4 to sequences flanking the mRNA start site in the thymidine kinase gene was not observed. Models for ICP4-mediated positive or negative regulation of HSV gene transcription are discussed.
INTRODUCTION
The genome of herpes simplex virus (HSV) contains approximately 70 genes. During the course of productive infection, transcription of viral genes is temporally and quantitatively regulated by cis-acting signals within the viral genome and by trans-acting factors encoded in both host and viral genes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The temporal pattern of expression for a given viral gene forms the basis for its classification as either an immediate early (alpha), early (beta), or late (gamma) gene (12) .
Five genes have been assigned to the IE class. These genes encode infected cell polypeptides (ICPs) 4, 0, 22, 27 and 47, which have apparent molecular weights of 175,000 (175k), 110k, 68k, 63k, and 12k, respectively (13, 14) . The region that spans nucleotides approximately -100 to +40 relative to the transcription initiation site (+1) in each IE gene contains sufficient information to function as a constitutive RNA polymerase II promoter in uninfected cells (5, 15) . Each IE gene promoter is regulated in a positive manner by cis-acting signals that are located in the region from -350 to -100 (A, 5, 16, 17) . This regulatory domain contains a binding site for a host cell protein (18) and is subject to positive regulation by a virion component designated as ct-TIF or Vmw65 (A, 8, [19] [20] [21] . When introduced by DNA transfection into uninfected cells, IE gene promoters function constitutively in the absence of viral proteins and are induced 10 to 40-fold in cells which contain a-TIF (8, 22, 23) .
The expression of IE genes is also subject to negative regulation at several steps in the pathway from transcription to translation (24) (25) (26) (27) . The decreased production of ICP4 mRNA that occurs within 1 hour postinfection (28) implies that negative regulation is achieved in part by reducing the rate of IE gene transcription. Of particular interest is the observation that transcription from an ICP4 gene promoter domain that spans nucleotides -108 to +30 is reduced in cells which are cotransfected with the ICP4 gene (29) . This suggests that ICP4 may play a role in negative regulation of IE gene expression.
The role of ICP4 in positive regulation of the early class of HSV genes at the transcriptional level has been well documented (26, (30) (31) (32) . However, attempts to define a cis-acting signal within the promoter-regulatory domain of an early gene which is required in vivo for induction by ICP4 have not been successful. All of the cis-acting domains which have been identified in the promoter-regulatory domain of the HSV-1 gene encoding thymidine kinase (tk) respond to proteins present in uninfected cells (1, 33, 34) . Coen et al (1) have predicted that induction of tk gene transcription is not mediated by a direct interaction between ICP4 and the tk gene . In this paper we describe results which are consistent with this prediction.
Previous reports have established that stable protein-DNA complexes containing ICP4 can be formed in vitro (35) (36) (37) (38) (39) . Based on results from mobility shift assays, Kristie and Roizman reported that there are binding sites for ICP4 in the promoterregulatory domains associated with the IE genes encoding ICP4, 0, and 27 (36) . Exonuclease III protection experiments revealed that the binding site in the ICP0 gene promoter is located between nucleotide positions -71 and -46 (37). Muller used a DMS interference assay to map a binding site for ICP4 that spans nucleotides -10 to +3 relative to the ICP4 mRNA cap site (39). We have demonstrated by a DNA binding immunoassay that two regions within the procaryotic vector pBR322 and one region approximately 100 bp upstream of the HSV glycoprotein D transcription initiation site contain specific sequences which interact, directly or indirectly, with ICP4 (38). We have designated these sequences as ICP4/protein binding sites to indicate our inadequate knowledge regarding other proteins which may be required for formation of ICP4:DNA complexes under the conditions of this assay. Examination of the sequences protected in DNase I footprinting experiments revealed that the hexanucleotide sequence 5'-ATCGTC-3' is located at the same relative position in all three binding sites.
A computer search revealed that this hexanucleotide sequence is located in only two (namely, ICP4 and ICPO) of the four HSV-1 IE gene promoter-regulatory domains (the promoter-regulatory domains for the genes encoding ICP22 and ICP47 are identical). In this paper we report that when cloned fragments from each of the IE gene promoter-regulatory domains were used as target DNAs in DNA binding immunoassays, ICP4/protein binding sites were detected in the promoter domains of the genes encoding ICPO and ICP4. No such sites were detected in the promoter-regulatory domains of genes encoding ICP22 and ICP27. DNase protection results revealed that the ICP4/protein binding site in the ICP4 gene promoter overlaps the ICP4 gene transcription initiation site, as shown previously by DMS interference (39). This location suggests that negative regulation of ICP4 gene expression may occur at the level of transcription initiation as a result of promoter occlusion by ICP4.
MATERIALS AND METHODS
Fraction VIII. Fraction VIII is the pooled peak of ICP4 that elutes from a DEAE-cellulose column in the purification scheme described previously (38, 40 DNA binding immunoassay. The DNA binding immunoassay was conducted as previously described (38). Plasmid DNAs were uniformly radiolabeled with 32 P in vivo so that all restriction fragments could be detected. Radiolabeled DNAs were digested with restriction enzymes and mixed with a 20-fold (by mass) ratio of unlabeled salmon sperm DNA in DNA binding buffer (DBB) (150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 2 mM mercaptoethanol, 0.5 mM EDTA, and 50 ug/ml BSA). A sample of fraction VIII was added and the mixture was incubated for 30 min at 22°C. Polyclonal antibody that is specific for ICP4 (44) was added and allowed to react for 15 min at 22"C. The immune complexes were precipitated by the addition of protein A-bearing S. aureus. DNA fragments were eluted from the washed innnunoprecipitate with buffer containing 2% NaDodSO*, resolved by electrophoresis in 5X polyacrylamide gels, and detected by autoradiography. 1A) . When used as a target DNA, this 525 bp fragment was immunoprecipitated (Fig. IB, lane 1) . When the Smal fragment was cleaved at position -103 with EcoRI, only the 302 bp EcoRI-Smal fragment from position -103 to +182 was immunoprecipitated (Fig.  IB, lane 3) . When the Smal fragment was cleaved at position +32 with BamHI, only the 358 bp Smal-BamHI fragment from position -326 to +32 was immunoprecipitated. When the Smal fragment was cleaved at position +1 with Pvul, neither subfragment was precipitated. These results demonstrate that an ICPA/protein binding site is located between positions -103 and +32 in the ICP4 gene and suggest that nucleotides flanking the Pvul site at +1 are required for formation of stable proteimDNA complexes that contain ICP4.
RESULTS

Mapping
The footprinting technique of Galas and Schmitz (47) was used to identify which nucleotides between positions -103 and +32 were protected by association with ICP4. A 332 bp fragment containing these nucleotides was labeled with 32 P at the 5' end of the EcoRI site (Fig. 1A) , incubated with fraction VIII, and then briefly exposed to DNase I. The resultant radiolabeled DNA fragments were resolved by electrophoresis through a sequencing gel and detected by autoradiography. In the absence of fraction VIII, a ladder of bands was generated in which the intensity of the bands reflected the relative preference of DNase I for particular cleavage sites in the DNA (Fig. 2A) . In the presence of fraction VIII, alterations in the pattern of DNase I cleavage were observed in Using a similar approach, we have observed a strong ICP4/protein binding site in the 77 bp BstNl fragment that extends from nucleotide -90 to -14 relative to the mRNA cap site in the ICP0 gene (49). We assume that this site corresponds to the region from -71 to -46 that was previously shown to contain an ICP4/protein binding site (37) and that includes the ATCGTC hexanucleotide sequence between -67 and -62 found during the computer search. We were unable to detect any strong binding sites in the promoter shared by the ICP22 and 47 genes using target DNAs that extended from -299 to -70, -97 to +7, or -57 to +201 relative to the mRNA cap site in this promoter (49). It should be noted that the fragment from -299 to -70 includes core sequences associated with the origin of DNA replication in the S component of the viral genome (50). DNA in DNA binding immunoassays with fraction VIII. Of the six cleavage products (Fig. 4A) , four are of particular interest, namely (i) a 490 bp fragment which extends from -709 to -220 relative to the tk gene, (ii) a 234 bp fragment which extends from -219 to +15 relative to the tk gene and contains the tk gene promotor-regulatory domains (1), (iii) a 346 bp fragment which contains the two strong ICP4/protein binding sites in the tet gene of the vector, and (iv) a 1702 bp fragment which contains a weak ICP4/protein binding site in the vector.
To ensure that any potential ICP4/protein binding sites in the viral DNA were not competed out with excess carreir DNA, a series of assays was performed in which the amount of target DNA was held constant and the mass ratio of carrier to target DNA was varied from 0 to 100. In the absence of competing DNA, the 1702 and 346 bp vector fragments were readily detectable in the immunoprecipitate (Fig. 4B) , whereas the 490 bp fragment was barely detectable and the 234 bp fragment was not seen. Thus, under the conditions of this assay, there are no detectable ICP4/protein binding sites within the sequences from -219 to +15 that define the known promoter-regulatory domains of the HSV-1 tk gene. The binding of ICP4 to the 490 bp fragment is extremely weak and has not been investigated further. Binding of ICP4 to a fragment from the tk gene that extends from nucleotide -709 to +53 was also extremely weak and binding to a fragment from +15 to +854 could not be detected (49).
Comparison of ICP4/protein binding sites. A comparison of the nucleotide sequences in ICP4/protein binding sites which have been identified (37-39) is shown in Figure 5 . The similarity of portions of these sites is striking. For example, there is a 14 bp region in each of the ICP4, gD, and tet-2 gene sites in which there are 11 or 12 perfect matches, 1 pyrimidine match, and 1 or 2 complete mismatches. This 14 bp region includes the sequence 5'-ATCGTC-3', which is present in all ICP4/protein binding sites which we have identified, and thus presumably forms part of the recognition sequence required for association of ICP4 with DNA.
DISCUSSION
We report that ICPA binds, either directly or indirectly, to sequences in the promoters of the immediate early HSV-1 genes encoding ICP4 and ICPO. These results confirm and extend the findings of Kristie and Roizman (36, 37) and Muller (39) . Muller demonstrated by DMS interference assays that the binding site in the ICP4 gene promoter includes nucleotides from position -10 to +3.
The DNase protection results presented here suggest that the binding site may be somewhat larger, extending from -10 to +20. Alternatively, the protection of sequences downstream from +3 may be attributed to steric hindrance of the DNase by an "overhanging" portion of protein bound upstream of +3.
We also report that, under the conditions of the DNA binding immunoassay, the association of ICP4 with the promoter-regulatory domains of the IE HSV-1 genes encoding ICPs 22, 27, or 47 or with the regulatory domain of the ICP4 gene was extremely weak at best. These results differ from those of Kristie and Roizman (36, 37) , who reported that the regulatory domains of the ICP4 and ICP27 genes contain ICP4/protein binding sites. We note that these two domains lack the ATCGTC hexanucleotide sequence and speculate that stable association of ICPA with the regulatory domains of the ICPA and ICP27 genes may require a factor which is present in nuclear extracts from infected cells (as prepared by Kristie and Roizman) but which is absent from more highly purified preparations of ICPA, such as fraction VIII used in this investigation.
As an extension of this idea, one could propose that ICPA is an effector protein which can "dock" with a variety of DNA binding proteins that recognize different sequences in the promoterregulatory domains of cellular and viral genes. Depending on the particular "docking" protein, the effect of this interaction could be either positive or negative. Thus, the interaction of ICPA with cellular proteins that bind to early viral promoters (such as the tk gene) might increase promoter strength, whereas the interaction of ICPA with factors that bind to immediate early viral promoters might decrease promoter strength. It should be noted that this model does not exclude the possibility that ICPA itself is a sequence-specific DNA binding protein. Given the size of the polypeptide (1298 amino acids, ref. 51), it is not unreasonable to suggest that ICPA has a domain for protein:DNA interactions as well as domains for protein:protein interactions.
The association of ICPA with nucleotides spanning the ICPA gene transcription initiation site is consistent with a model in which ICPA represses initiation of transcription of the ICPA gene by hindering the movement of RNA polymerase. The role of the ICPA/protein binding site in the regulation of ICPO gene transcription is not as obvious. However, it may be more than coincidental that the ATCGTC hexanucleotide component of the ICP4/protein binding site at positions -66 to -61 is located immediately downstream from a CCAAT pentanucleotide at positions -75 to -71 that may bind the cellular transcription factor CTF/NF-1 (52) or CBP (53). Furthermore, the ICPA/protein binding site overlaps a GGGCGG hexanucleotide at positions -57 to -52 that may bind the cellular transcription factor Spl (6). It is also noteworthy that all three sites are apparently on the same face of the DNA helix. Thus, expression of the ICPA gene may be exquisitely regulated in both a positive and a negative manner by multiple interactions among three different regulatory proteins that might bind to the ICPO promoter within a 25 bp region (37) .
In fact, Gelman and Silverstein (9) have reported that the ICPO gene can be regulated either positively or negatively by ICP4, depending on the ratio of effector protein to target DNA.
We also report a direct demonstration that ICP4 itself does not bind with high affinity to the known promoter-regulatory domains of the HSV-1 thymidine kinase gene. Negative binding results were also obtained with a DNA fragment spanning nucleotides from -410 to +140 in the ICP4-inducible (11) promoter associated with the HSV-2 early gene encoding the 38k subunit of ribonucleotide reductase (49). These results support the proposal by Coen et al (1) that "protein products of HSV immediate early regulatory genes do not bind directly to an induction-specific domain of the tk promoter" and suggest that induction by ICP4 is mediated in an indirect manner. Experiments to test indirect mechanisms for ICP4-induced early gene expression are being conducted with in vitro transcription systems (35, 54) , which ultimately must be refined to their essential components before the definitive analyses can be performed.
